Improving medication adherence and outcomes in adult kidney transplant patients using a personal systems approach

SystemCHANGE™ results of the MAGIC randomized clinical trial

Cynthia L. Russell, Donna Hathaway, Laura M. Remy, Dana Aholt, Debra Clark, Courtney Miller, Catherine Ashbaugh, Mark Wakefield, Sangbeak Ye, Vincent S. Staggs, Rebecca J. Ellis, Kathy Goggin

Research output: Contribution to journalArticle

Abstract

This study determined if a SystemCHANGE™ intervention was more efficacious than attention control in increasing immunosuppressive medication adherence and improving outcomes in adult kidney transplant recipients during a 6-month intervention phase and subsequent 6-month (no intervention) maintenance phase. The SystemCHANGE™ intervention taught patients to use person-level quality improvement strategies to link adherence to established daily routines, environmental cues, and supportive people. Eighty-nine patients (average age 51.8 years, 58% male, 61% African American) completed the 6-month intervention phase. Using an intent-to-treat analysis, at 6 months, medication adherence for SystemCHANGE™ (median 0.91, IQR 0.76-0.96) and attention control (median 0.67, IQR 0.52-0.72) patients differed markedly (difference in medians 0.24, 95% CI 0.13-0.30, P <.001). At the conclusion of the subsequent 6-month maintenance phase, the gap between medication adherence for SystemCHANGE™ (median 0.77, IQR 0.56-0.94) and attention control (median 0.60, IQR 0.44-0.73) patients remained large (difference in medians 0.17, 95% CI 0.06-0.33, P =.004). SystemCHANGE™ patients evidenced lower mean creatinine and BUN at 12 months and more infections at 6 and 12 months. This first fully powered RCT testing SystemCHANGE™ to improve and maintain medication adherence in kidney transplant recipients demonstrated large, clinically meaningful improvements in medication adherence. Clinical Trial Registration: NCT02416479.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Medication Adherence
Health Services Research
Immunosuppressive Agents
Systems Analysis
Randomized Controlled Trials
Clinical Trials
Transplants
Kidney
Maintenance
Blood Urea Nitrogen
Quality Improvement
African Americans
Cues
Creatinine
Transplantation
Infection

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Improving medication adherence and outcomes in adult kidney transplant patients using a personal systems approach : SystemCHANGE™ results of the MAGIC randomized clinical trial. / Russell, Cynthia L.; Hathaway, Donna; Remy, Laura M.; Aholt, Dana; Clark, Debra; Miller, Courtney; Ashbaugh, Catherine; Wakefield, Mark; Ye, Sangbeak; Staggs, Vincent S.; Ellis, Rebecca J.; Goggin, Kathy.

In: American Journal of Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Russell, Cynthia L. ; Hathaway, Donna ; Remy, Laura M. ; Aholt, Dana ; Clark, Debra ; Miller, Courtney ; Ashbaugh, Catherine ; Wakefield, Mark ; Ye, Sangbeak ; Staggs, Vincent S. ; Ellis, Rebecca J. ; Goggin, Kathy. / Improving medication adherence and outcomes in adult kidney transplant patients using a personal systems approach : SystemCHANGE™ results of the MAGIC randomized clinical trial. In: American Journal of Transplantation. 2019.
@article{f7d4f2c2bc8e46e39786446a0cff713d,
title = "Improving medication adherence and outcomes in adult kidney transplant patients using a personal systems approach: SystemCHANGE™ results of the MAGIC randomized clinical trial",
abstract = "This study determined if a SystemCHANGE™ intervention was more efficacious than attention control in increasing immunosuppressive medication adherence and improving outcomes in adult kidney transplant recipients during a 6-month intervention phase and subsequent 6-month (no intervention) maintenance phase. The SystemCHANGE™ intervention taught patients to use person-level quality improvement strategies to link adherence to established daily routines, environmental cues, and supportive people. Eighty-nine patients (average age 51.8 years, 58{\%} male, 61{\%} African American) completed the 6-month intervention phase. Using an intent-to-treat analysis, at 6 months, medication adherence for SystemCHANGE™ (median 0.91, IQR 0.76-0.96) and attention control (median 0.67, IQR 0.52-0.72) patients differed markedly (difference in medians 0.24, 95{\%} CI 0.13-0.30, P <.001). At the conclusion of the subsequent 6-month maintenance phase, the gap between medication adherence for SystemCHANGE™ (median 0.77, IQR 0.56-0.94) and attention control (median 0.60, IQR 0.44-0.73) patients remained large (difference in medians 0.17, 95{\%} CI 0.06-0.33, P =.004). SystemCHANGE™ patients evidenced lower mean creatinine and BUN at 12 months and more infections at 6 and 12 months. This first fully powered RCT testing SystemCHANGE™ to improve and maintain medication adherence in kidney transplant recipients demonstrated large, clinically meaningful improvements in medication adherence. Clinical Trial Registration: NCT02416479.",
author = "Russell, {Cynthia L.} and Donna Hathaway and Remy, {Laura M.} and Dana Aholt and Debra Clark and Courtney Miller and Catherine Ashbaugh and Mark Wakefield and Sangbeak Ye and Staggs, {Vincent S.} and Ellis, {Rebecca J.} and Kathy Goggin",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ajt.15528",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Improving medication adherence and outcomes in adult kidney transplant patients using a personal systems approach

T2 - SystemCHANGE™ results of the MAGIC randomized clinical trial

AU - Russell, Cynthia L.

AU - Hathaway, Donna

AU - Remy, Laura M.

AU - Aholt, Dana

AU - Clark, Debra

AU - Miller, Courtney

AU - Ashbaugh, Catherine

AU - Wakefield, Mark

AU - Ye, Sangbeak

AU - Staggs, Vincent S.

AU - Ellis, Rebecca J.

AU - Goggin, Kathy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This study determined if a SystemCHANGE™ intervention was more efficacious than attention control in increasing immunosuppressive medication adherence and improving outcomes in adult kidney transplant recipients during a 6-month intervention phase and subsequent 6-month (no intervention) maintenance phase. The SystemCHANGE™ intervention taught patients to use person-level quality improvement strategies to link adherence to established daily routines, environmental cues, and supportive people. Eighty-nine patients (average age 51.8 years, 58% male, 61% African American) completed the 6-month intervention phase. Using an intent-to-treat analysis, at 6 months, medication adherence for SystemCHANGE™ (median 0.91, IQR 0.76-0.96) and attention control (median 0.67, IQR 0.52-0.72) patients differed markedly (difference in medians 0.24, 95% CI 0.13-0.30, P <.001). At the conclusion of the subsequent 6-month maintenance phase, the gap between medication adherence for SystemCHANGE™ (median 0.77, IQR 0.56-0.94) and attention control (median 0.60, IQR 0.44-0.73) patients remained large (difference in medians 0.17, 95% CI 0.06-0.33, P =.004). SystemCHANGE™ patients evidenced lower mean creatinine and BUN at 12 months and more infections at 6 and 12 months. This first fully powered RCT testing SystemCHANGE™ to improve and maintain medication adherence in kidney transplant recipients demonstrated large, clinically meaningful improvements in medication adherence. Clinical Trial Registration: NCT02416479.

AB - This study determined if a SystemCHANGE™ intervention was more efficacious than attention control in increasing immunosuppressive medication adherence and improving outcomes in adult kidney transplant recipients during a 6-month intervention phase and subsequent 6-month (no intervention) maintenance phase. The SystemCHANGE™ intervention taught patients to use person-level quality improvement strategies to link adherence to established daily routines, environmental cues, and supportive people. Eighty-nine patients (average age 51.8 years, 58% male, 61% African American) completed the 6-month intervention phase. Using an intent-to-treat analysis, at 6 months, medication adherence for SystemCHANGE™ (median 0.91, IQR 0.76-0.96) and attention control (median 0.67, IQR 0.52-0.72) patients differed markedly (difference in medians 0.24, 95% CI 0.13-0.30, P <.001). At the conclusion of the subsequent 6-month maintenance phase, the gap between medication adherence for SystemCHANGE™ (median 0.77, IQR 0.56-0.94) and attention control (median 0.60, IQR 0.44-0.73) patients remained large (difference in medians 0.17, 95% CI 0.06-0.33, P =.004). SystemCHANGE™ patients evidenced lower mean creatinine and BUN at 12 months and more infections at 6 and 12 months. This first fully powered RCT testing SystemCHANGE™ to improve and maintain medication adherence in kidney transplant recipients demonstrated large, clinically meaningful improvements in medication adherence. Clinical Trial Registration: NCT02416479.

UR - http://www.scopus.com/inward/record.url?scp=85070911201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070911201&partnerID=8YFLogxK

U2 - 10.1111/ajt.15528

DO - 10.1111/ajt.15528

M3 - Article

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -